Publications by authors named "Peter L Samuels"
Article Synopsis
- Multiple studies have shown changes in B- and T-cell responses in individuals with type 1 diabetes (T1D), but it’s unclear if these changes cause the disease or result from it.
- Researchers used samples from the TrialNet Pathway to Prevention study to analyze T-cell responses to certain stimuli, the B-cell composition, and their responses to specific receptors.
- The findings highlight key immune differences across disease stages, including early indicators in at-risk individuals, and how these immune traits evolve, potentially influencing treatment approaches.
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2-4 mg/day rapamycin orally for 3 months and 4.
View Article and Find Full Text PDFWe describe a role for ECM as a biosensor for inflammatory microenvironments that plays a critical role in peripheral immune tolerance. We show that hyaluronan (HA) promotes induction of Foxp3- IL-10-producing regulatory T cells (TR1) from conventional T-cell precursors in both murine and human systems. This is, to our knowledge, the first description of an ECM component inducing regulatory T cells.
View Article and Find Full Text PDF